Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases

DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G., ÖZKAN C., BİÇER Ö. S., TEKİN M.

ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA, cilt.51, sa.1, ss.1-6, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.aott.2016.03.004
  • Dergi Adı: ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-6
  • Anahtar Kelimeler: Denosumab, Recurrence, Giant cell tumor, ARTERIAL EMBOLIZATION, POSTMENOPAUSAL WOMEN, ZOLEDRONIC ACID, OPEN-LABEL, EXPRESSION, METASTASES, CURETTAGE, RECURRENT, THERAPY
  • Çukurova Üniversitesi Adresli: Evet

Özet

Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclear factor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of GCT with denosumab and to assess adverse effect profile and recurrence rate.